BRPI0509927A - composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina - Google Patents

composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina

Info

Publication number
BRPI0509927A
BRPI0509927A BRPI0509927-7A BRPI0509927A BRPI0509927A BR PI0509927 A BRPI0509927 A BR PI0509927A BR PI0509927 A BRPI0509927 A BR PI0509927A BR PI0509927 A BRPI0509927 A BR PI0509927A
Authority
BR
Brazil
Prior art keywords
composition
antisense oligonucleotide
matter
therapeutically effective
effective combination
Prior art date
Application number
BRPI0509927-7A
Other languages
English (en)
Inventor
Bharvin Kumar Patel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0509927A publication Critical patent/BRPI0509927A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

COMPOSIçãO FARMACêUTICA, USO DE UMA COMPOSIçãO DE MATéRIA, E, USO DE UMA COMBINAçãO TERAPEUTICAMENTE EFICAZ DE UM OLIGONUCLEOTìDEO ANTI-SENTIDO DE SURVIVINA E CLORIDRATO DE GEMCITABINA. A presente invenção diz respeito a um método de tratar o câncer em um paciente compreendendo a administração de uma quantidade eficaz de um oligonucleotídeo anti-sentido de Survivina em combinação com uma quantidade eficaz de um agente anti-cancerígeno adicional.
BRPI0509927-7A 2004-04-22 2005-04-15 composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina BRPI0509927A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56454004P 2004-04-22 2004-04-22
PCT/US2005/012968 WO2005107771A2 (en) 2004-04-22 2005-04-15 Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0509927A true BRPI0509927A (pt) 2007-09-25

Family

ID=35094133

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509927-7A BRPI0509927A (pt) 2004-04-22 2005-04-15 composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina

Country Status (17)

Country Link
US (3) US20070244065A1 (pt)
EP (3) EP1913947B1 (pt)
JP (1) JP2007533742A (pt)
CN (2) CN101683355A (pt)
AT (2) ATE538800T1 (pt)
AU (1) AU2005240020B2 (pt)
BR (1) BRPI0509927A (pt)
CA (1) CA2562750A1 (pt)
CY (2) CY1110440T1 (pt)
DE (1) DE602005008241D1 (pt)
DK (2) DK1913947T3 (pt)
ES (2) ES2308488T3 (pt)
MX (1) MXPA06012132A (pt)
PL (2) PL1763356T3 (pt)
PT (2) PT1913947E (pt)
SI (2) SI1913947T1 (pt)
WO (1) WO2005107771A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010003057A2 (en) * 2008-07-03 2010-01-07 Mayo Foundation For Medical Education And Research Treating cancer
FR2955112B1 (fr) 2010-01-14 2012-01-20 Isp Investments Inc Nouveaux peptides anti-age modulateurs de la survivine et compositions les comprenant
WO2012058462A2 (en) * 2010-10-29 2012-05-03 Isis Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
EP2707030B1 (en) 2011-05-09 2020-02-19 Mayo Foundation For Medical Education And Research Cancer treatments
WO2014055415A1 (en) 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments
US10213513B2 (en) 2014-06-16 2019-02-26 Mayo Foundation For Medical Education And Research Treating myelomas
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research INTERFERON CANCER TREATMENT METHODS
AU2017217881B2 (en) 2016-02-12 2022-11-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
CA3018341A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
AU2017238118A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
KR102462041B1 (ko) 2016-09-01 2022-11-02 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물
WO2018045238A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Methods and compositions for targeting t-cell cancers
EP3509643A1 (en) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
CN109843924A (zh) 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0184365B1 (en) * 1984-12-04 1993-08-04 Eli Lilly And Company Improvements in the treatment of tumors in mammals
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6077709A (en) * 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6838283B2 (en) * 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
PT1592793E (pt) * 2003-02-10 2009-09-30 Santaris Pharma As Compostos oligoméricos para a modulação da expressão de survivina

Also Published As

Publication number Publication date
WO2005107771A3 (en) 2006-06-08
PL1913947T3 (pl) 2012-05-31
EP2145626A1 (en) 2010-01-20
CY1112397T1 (el) 2015-12-09
WO2005107771A2 (en) 2005-11-17
EP1763356A2 (en) 2007-03-21
SI1913947T1 (sl) 2012-02-29
US20090247611A1 (en) 2009-10-01
PT1763356E (pt) 2008-09-05
EP1763356B1 (en) 2008-07-16
CY1110440T1 (el) 2015-04-29
ATE401088T1 (de) 2008-08-15
EP1913947B1 (en) 2011-12-28
EP1913947A1 (en) 2008-04-23
AU2005240020A1 (en) 2005-11-17
DK1913947T3 (da) 2012-02-06
DE602005008241D1 (de) 2008-08-28
PT1913947E (pt) 2012-01-19
US20120022140A1 (en) 2012-01-26
US20070244065A1 (en) 2007-10-18
ES2308488T3 (es) 2008-12-01
PL1763356T3 (pl) 2008-12-31
CN101683355A (zh) 2010-03-31
AU2005240020B2 (en) 2011-02-10
DK1763356T3 (da) 2008-10-13
JP2007533742A (ja) 2007-11-22
MXPA06012132A (es) 2007-01-17
SI1763356T1 (sl) 2008-12-31
ATE538800T1 (de) 2012-01-15
CA2562750A1 (en) 2005-11-17
ES2376484T3 (es) 2012-03-14
CN1950094A (zh) 2007-04-18

Similar Documents

Publication Publication Date Title
BRPI0509927A (pt) composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina
BRPI0906181A2 (pt) "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
WO2006053049A3 (en) Herbal composition phy906 and its use in chemotherapy
CY1112889T1 (el) Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
BR0316004A (pt) Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina
BRPI0615157A2 (pt) composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto
BRPI0511139A (pt) compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
DE602006014579D1 (de) Heteroalkylgebundene pyrimidinderivate
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
UA103614C2 (uk) Лікарський засіб, що містить комбінацію інгібітора кінази та анти-гліпікан 3-антитіла, для лікування раку печінки
SV2008002958A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania referencia cruzada ref. prd2592sv
MX2007004955A (es) Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
BRPI0511475A (pt) combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
FR2866885B1 (fr) Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique
BRPI0519006A2 (pt) uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
BRPI0416870A (pt) composições anticáncer sinergìticas
BRPI0507985A (pt) derivados de piperazina uréia para o tratamento de endometriose
BRPI0519023A2 (pt) composiÇço farmacÊutica contendo pelo menos um derivado de dolastatina 10
IL197769A (en) The history of morphine, medicinal preparations containing them and their use in the preparation of pain medication
BR0316021A (pt) Comibinação compreendendo um inibidor de cdk e cisplatina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.